CP-154,526 is a potent and selective
antagonist of the
corticotropin releasing hormone receptor 1 developed by
Pfizer
Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...
.
CP-154,526 is under investigation for the potential treatment of
alcoholism
Alcoholism is, broadly, any drinking of alcohol that results in significant mental or physical health problems. Because there is disagreement on the definition of the word ''alcoholism'', it is not a recognized diagnostic entity. Predomi ...
.
See also
*
Antalarmin
Antalarmin (CP-156,181) is a drug that acts as a CRH1 antagonist.
Corticotropin-releasing hormone (CRH), also known as Corticotropin-releasing factor, is an endogenous peptide hormone released in response to various triggers such as chronic stres ...
*
Pexacerfont
*
Corticotropin releasing hormone antagonist
References
Further reading
*
*
*
External links
*
Anxiolytics
Corticotropin-releasing hormone antagonists
Pyrrolopyrimidines
Pfizer brands
{{Anxiolytic-stub